...
首页> 外文期刊>Lancet Neurology >Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial.
【24h】

Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial.

机译:用恒流装置刺激丘脑深部脑部帕金森氏病:一项开放标签的随机对照试验。

获取原文
获取原文并翻译 | 示例
           

摘要

The effects of constant-current deep brain stimulation (DBS) have not been studied in controlled trials in patients with Parkinson's disease. We aimed to assess the safety and efficacy of bilateral constant-current DBS of the subthalamic nucleus.This prospective, randomised, multicentre controlled trial was done between Sept 26, 2005, and Aug 13, 2010, at 15 clinical sites specialising in movement disorders in the USA. Patients were eligible if they were aged 18-80 years, had Parkinson's disease for 5 years or more, and had either 6 h or more daily off time reported in a patient diary of moderate to severe dyskinesia during waking hours. The patients received bilateral implantation in the subthalamic nucleus of a constant-current DBS device. After implantation, computer-generated randomisation was done with a block size of four, and patients were randomly assigned to the stimulation or control group (stimulation:control ratio 3:1). The control group received implantation without activation for 3 months. No blinding occurred during this study, and both patients and investigators were aware of the treatment group. The primary outcome variable was the change in on time without bothersome dyskinesia (ie, good quality on time) at 3 months as recorded in patients' diaries. Patients were followed up for 1 year. This trial is registered with ClinicalTrials.gov, number NCT00552474.Of 168 patients assessed for eligibility, 136 had implantation of the constant-current device and were randomly assigned to receive immediate (101 patients) or delayed (35 patients) stimulation. Both study groups reported a mean increase of good quality on time after 3 months, and the increase was greater in the stimulation group (4·27 h vs 1·77 h, difference 2·51 [95% CI 0·87-4·16]; p=0·003). Unified Parkinson's disease rating scale motor scores in the off-medication, on-stimulation condition improved by 39% from baseline (24·8 vs 40·8). Some serious adverse events occurred after DBS implantation, including infections in five (4%) of 136 patients and intracranial haemorrhage in four (3%) patients. Stimulation of the subthalamic nucleus was associated with dysarthria, fatigue, paraesthesias, and oedema, whereas gait problems, disequilibrium, dyskinesia, and falls were reported in both groups.Constant-current DBS of the subthalamic nucleus produced significant improvements in good quality on time when compared with a control group without stimulation. Future trials should compare the effects of constant-current DBS with those of voltage-controlled stimulation.St Jude Medical Neuromodulation Division.
机译:在帕金森氏病患者的对照试验中,尚未研究恒流深部脑刺激(DBS)的作用。我们旨在评估丘脑下核双侧恒流DBS的安全性和有效性。这项前瞻性,随机,多中心对照试验于2005年9月26日至2010年8月13日之间在15个专门研究运动障碍的临床部位进行美国。如果患者在醒来时的中度至重度运动障碍日记中报告了年龄在18-80岁,患有帕金森氏病5年或更长时间,每天休息6小时或更长时间的患者,则符合条件。患者接受了恒流DBS装置的丘脑下核的双侧植入。植入后,计算机生成的随机区组大小为4,将患者随机分配到刺激组或对照组(刺激:对照比率3:1)。对照组接受了3个月未激活的植入。在该研究中没有致盲,并且患者和研究者都知道治疗组。主要结果变量是患者日记中记录的在3个月时无烦躁性运动障碍(即准时质量好)的准时变化。随访1年。该试验已在ClinicalTrials.gov上注册,编号为NCT00552474。在168例符合资格的患者中,有136例植入了恒流装置,并随机分配接受立即(101例)或延迟(35例)刺激。两个研究组均报告3个月后按时平均质量提高,而刺激组的提高幅度更大(4·27 h对1·77 h,差异2·51 [95%CI 0·87-4· 16]; p = 0·003)。在药物外,刺激条件下,统一的帕金森氏病评分量表运动评分比基线提高了39%(24·8比40·8)。 DBS植入后发生了一些严重的不良事件,包括136名患者中的五名(4%)感染和四名(3%)的患者颅内出血。丘脑底核的刺激与构音困难,疲劳,感觉异常和水肿有关,而两组均报告了步态问题,不平衡,运动障碍和跌倒。与没有刺激的对照组相比。未来的试验应将恒流DBS与电压控制刺激的效果进行比较。StJude医学神经调节部门。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号